Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

1. Bidard, F.-C.
2. Kaklamani, V.G.
3. Neven, P.
4. Streich, G.
5. Montero, A.J.
6. Forget, F.
7. Mouret-Reynier, M.-A.
8. Sohn, J.H.
9. Taylor, D.
10. Harnden, K.K.
11. Khong, H.
12. Kocsis, J.
13. Dalenc, F.
14. Dillon, P.M.
15. Babu, S.
16. Waters, S.
17. Deleu, I.
18. García Sáenz, J.A.
19. Bria, E.
20. Cazzaniga, M.
21. Lu, J.
22. Aftimos, P.
23. Cortés, J.
24. Liu, S.
25. Tonini, G.
26. Laurent, D.
27. Habboubi, N.
28. Conlan, M.G.
29. Bardia, A.
30. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1200/JCO.22.00338 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus